SSelectStock
Sign in

HALEOSLABSHALEOS LABS LIMITED

Pharma · Biotechnology · NSE · as of 2026-07-20 (delayed ~30 min in market hours)

1,589.10
1.15%
60Decent

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)480.40
P/E27.79
P/B2.25
PEG
ROE %8.06
ROCE %9.00
Debt / Equity0.48
EPS57.19
Revenue Growth %-15.70
Profit Growth %-85.40
Dividend Yield %0.09
Promoter Holding %74.97
FII Holding %0.00
DII Holding %
Beta0.37

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

Pullback to 21-EMALONG62%1,589.101,505.141,789.102.38
HOLDConviction 62%

The picture

  • Debt/Equity: 0.48
  • Promoter holding: 75.0%
  • Valuation vs sector: P/E 27.8 vs sector 38.6
  • RSI: 56
  • MACD: bullish
  • Price vs EMA21: above
  • Pullback to 21-EMA signal (setup quality 62%)

Bull case

  • Debt/Equity: 0.48
  • Promoter holding: 75.0%
  • Valuation vs sector: P/E 27.8 vs sector 38.6
  • RSI: 56

Bear case

  • Revenue growth: -15.7% YoY
  • Profit growth: -85.4% YoY
  • Trend strength (ADX): 18
  • Volume: 0.2x 20-day average

Key risks

  • Elevated volatility / drawdown profile — size positions accordingly
  • Weak fundamentals — technical strength may not sustain
  • Revenue growth: -15.7% YoY
  • Profit growth: -85.4% YoY

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹1,589.10
Stop Loss
₹1,379.19
risk 13.2%
Target 1 (1.5R)
₹1,903.97
+19.8%
Target 2 (3R)
₹2,218.84
+39.6%
Support (20d)
₹1,312.10
Resistance (52w)
₹1,774.00
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹209.91/share
ATR (volatility)
₹83.96
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹83.96). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental
40
Technical
69
Momentum
86
Risk (safety)
42

Peers — Pharma

PGHL 0.78%
84
AJANTPHARM 1.45%
82
HESTERBIO 3.09%
81
LUPIN 1.44%
80
SUNPHARMA 1.23%
80
CORONA 0.78%
79

About

Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products. The company was formerly known as SMS Lifesciences India Limited and changed its name to Haleos Labs Limited in August 2025. Haleos Labs Limited was founded in 1990 and is based in Hyderabad, India.